• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Basic Materials·CAMLINFINE.NS
Share

Camlin Fine Sciences Limited Stocks

₹ 124.85Last Updated 15.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

₹ 258.99M

₹ 124.85
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Camlin Fine Sciences Limited, an India-based company headquartered in Mumbai and established in 1931 (originally as Camlin Fine Chemicals Limited until August 2011), is involved in the global research, development, production, and distribution of a diverse range of specialty chemicals, ingredients, and additive formulations. The company offers extensive shelf-life extension solutions under its Xtendra and NaSure brands. These include various antioxidants such as Tertiary Butyl Hydroquinone, Butylated Hydroxy Anisole, and Ascorbyl palmitate, alongside natural alternatives like mixed tocopherols, green tea extract, rosemary extract, and acerola extract. Additionally, its offerings comprise mold inhibitors, preservatives, acidifiers, antibacterial agents, toxin binders, pellet binders, and growth promoters. Its product line also features aroma ingredients, notably vanillin and ethyl vanillin, as well as nutraceuticals sourced through fermentation and plant extraction processes. Furthermore, Camlin Fine Sciences provides performance chemicals like hydroquinone and catechol, and a selection of downstream fine chemicals, including Guaiacol, Veratrole, TBC, MEHQ, and HQEE. These versatile products cater to numerous industries worldwide, encompassing food and beverage, pet food and animal nutrition, biodiesel, aquaculture, rendering, petrochemicals, agrochemicals, pharmaceuticals, polymers, dyes and pigments, biscuits and cookies, chocolate and confectionery, fragrance manufacturing, bakery, flavor, electroplating, and dietary supplements. The company actively engages in international exports of its goods.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, overvalued o

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of CAMLINFINE.NS is 183 and suggests 46.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.07.2026 10:51

SpaceX canceled the Starship launch due to engine problems. The stock price fell again.

17.07.2026 10:35

Top Stories This Morning: SpaceX Cancels Starship Launch; Tech Stocks Under Pressure

17.07.2026 09:30

Berkshire Hathaway may have accelerated its share buyback. This was indicated in Buffett's documents

17.07.2026 08:30

Lilly to Acquire Psychedelic Drug Developer for $3.8 Billion. Are There Any Prospects?

17.07.2026 07:30

Netflix is expecting a slowdown in revenue growth for the second consecutive quarter. Its stock plummeted 8%.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026